Your browser is no longer supported. Please, upgrade your browser.
Settings
PBYI Puma Biotechnology, Inc. daily Stock Chart
PBYI [NASD]
Puma Biotechnology, Inc.
Index- P/E- EPS (ttm)-8.08 Insider Own11.60% Shs Outstand37.25M Perf Week0.88%
Market Cap2.99B Forward P/E- EPS next Y-4.16 Insider Trans-31.76% Shs Float31.97M Perf Month52.57%
Income-277.90M PEG- EPS next Q-2.03 Inst Own95.30% Short Float26.09% Perf Quarter93.14%
Sales- P/S- EPS this Y-11.30% Inst Trans9.97% Short Ratio5.23 Perf Half Y128.96%
Book/sh4.53 P/B17.72 EPS next Y51.10% ROA-143.60% Target Price95.43 Perf Year157.71%
Cash/sh5.21 P/C15.41 EPS next 5Y- ROE-186.70% 52W Range27.64 - 92.00 Perf YTD161.40%
Dividend- P/FCF- EPS past 5Y-44.40% ROI- 52W High-6.03% Beta0.58
Dividend %- Quick Ratio4.70 Sales past 5Y- Gross Margin- 52W Low212.83% ATR5.21
Employees160 Current Ratio4.70 Sales Q/Q- Oper. Margin- RSI (14)73.46 Volatility4.85% 6.54%
OptionableYes Debt/Eq0.00 EPS Q/Q9.70% Profit Margin- Rel Volume0.76 Prev Close80.25
ShortableYes LT Debt/Eq0.00 EarningsMay 09 Payout- Avg Volume1.60M Price86.45
Recom1.70 SMA208.86% SMA5059.98% SMA20089.83% Volume1,204,829 Change7.73%
Jun-06-17Reiterated RBC Capital Mkts Sector Perform $60 → $88
May-25-17Reiterated RBC Capital Mkts Sector Perform $40 → $60
Mar-02-17Reiterated RBC Capital Mkts Sector Perform $48 → $17
Sep-22-16Reiterated Credit Suisse Outperform $54 → $111
Sep-21-16Upgrade Stifel Hold → Buy $61 → $88
Mar-29-16Downgrade RBC Capital Mkts Outperform → Sector Perform $103 → $36
Jan-21-16Initiated Credit Suisse Outperform
Dec-14-15Upgrade Citigroup Neutral → Buy
Sep-03-15Initiated Citigroup Neutral
Aug-27-15Initiated JP Morgan Overweight $122
Jan-23-15Initiated RBC Capital Mkts Outperform $282
Aug-19-14Resumed Stifel Hold
Jul-23-14Reiterated UBS Buy $125 → $325
Dec-19-13Reiterated UBS Buy $61 → $125
Dec-19-13Downgrade Stifel Buy → Hold
Jul-22-13Reiterated Stifel Buy $42 → $64
Jun-03-13Reiterated UBS Buy $35 → $49
Mar-25-13Reiterated Stifel Buy $32 → $42
Mar-20-13Reiterated UBS Buy $27 → $35
Jun-20-17 09:43AM  Big Money Flowing Into Biotech Stocks - Again Forbes
Jun-15-17 05:24PM  Puma (PBYI) Stock Surges as Neratinib Nears FDA Approval Zacks
Jun-13-17 11:57AM  The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Puma Biotechnology, Inc. Shareholders and a Lead Plaintiff Deadline of July 7, 2017 Business Wire
Jun-12-17 04:10PM  PUMA BIOTECHNOLOGY LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing in Puma Biotechnology, Inc. to Contact the Firm Accesswire
11:56AM  The Klein Law Firm Announces a Class Action Filed on Behalf of Puma Biotechnology, Inc. Shareholders and a Lead Plaintiff Deadline of July 7, 2017 Business Wire
Jun-09-17 07:35PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI Accesswire
Jun-08-17 11:47AM  PBYI SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Puma Biotechnology, Inc. and a Lead Plaintiff Deadline of July 7, 2017 Business Wire
Jun-07-17 10:39AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Puma Biotechnology, Inc. (PBYI) and Lead Plaintiff Deadline: July 7, 2017 Accesswire
Jun-06-17 04:34PM  3 Takeaways From Monday's ASCO Meetings: Puma Biotech, Incyte, Celgene Benzinga
04:04PM  Tesla Seen Rising 26% In Model 3 'Bull Case'; Puma, Microchip, Ulta Price Targets Hiked Investor's Business Daily
08:15AM  Corporate News Blog - Puma Biotech Announced Positive Results from PB272 Phase-II Data at the ASCO, 2017 Accesswire
Jun-05-17 02:14PM  INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Puma Biotechnology, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 7, 2017 Business Wire
09:20AM  Lawsuit for Investors in (NASDAQ: PBYI) Shares Against Puma Biotechnology Inc. Announced by Shareholders Foundation Accesswire
07:30AM  'APHINITY' Study Spells Major Trouble for Roche, Another Win for Puma Bio TheStreet.com
Jun-03-17 03:50PM  Puma Biotechnology Announces Positive PB272 Phase II Data from TBCRC 022 Trial in Patients with HER2-Positive Metastatic Breast Cancer with Brain Metastases at the 2017 ASCO Annual Meeting Business Wire
Jun-02-17 08:00PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI Accesswire
12:52PM  PBYI INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Puma Biotechnology, Inc. and a Lead Plaintiff Deadline of July 7, 2017 Business Wire
09:30AM  Universal Display, Hewlett Packard, Regeneron Pharmaceuticals, Sangamo Therapeutics and Puma Biotechnology highlighted as Zacks Bull and Bear of the Day Zacks
Jun-01-17 04:29PM  PUMA BIOTECHNOLOGY LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Puma Biotechnology, Inc. To Contact The Firm GlobeNewswire +6.73%
May-31-17 04:17PM  Puma Biotechnology to Present at the Jefferies 2017 Healthcare Conference Business Wire
May-30-17 10:59AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Puma Biotechnology, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 7, 2017 Business Wire
May-26-17 07:00PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI Accesswire
09:48AM  Puma Soaring After Neratinib FDA Panel Win, Time to Buy? Zacks
07:11AM  Will Puma Biotechnology (PBYI) Continue to Surge Higher? Zacks
May-25-17 11:18AM  Bullish Puma Investor Talks Neratinb FDA Panel Win, Next Steps and Takeout Potential TheStreet.com
10:36AM  INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Puma Biotechnology, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 7, 2017 - PBYI Accesswire
09:37AM  Biotech Movers: Positive Phase Three Results For Roclatan Send Aerie Shares Soaring TheStreet.com
08:43AM  Biotech And Pharma Industry And Stock News Investor's Business Daily
08:15AM  Puma Biotechnology (PBYI) Jumps: Stock Adds 29.7% in Session Zacks
May-24-17 04:38PM  This Biotech Stock Has Soared 84% This Week On Breast-Cancer Drug News Investor's Business Daily +29.67%
04:17PM  Why Abercrombie & Fitch, Triumph Group, and Puma Biotechnology Jumped Today Motley Fool
03:49PM  Why Puma Biotechnology Inc Jumped Higher Today Motley Fool
02:54PM  Puma Biotech shares surge 20% after FDA advisory committee votes in favor of approving breast cancer drug MarketWatch
01:36PM  Puma Biotech Gets Favorable FDA Vote On Neratinib Benzinga
01:29PM  Puma Biotechnology Receives FDA Advisory Committee Support for Neratinib Business Wire
12:32PM  FDA Panel Votes 12 To 4 to Approve Puma's Breast Cancer Drug Forbes
10:38AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Puma Biotechnology, Inc. (PBYI) and Lead Plaintiff Deadline: July 7, 2017 Accesswire
08:12AM  Puma Biotechnology FDA Live Blog Forbes
May-23-17 08:59AM  The Current State Of The Breast Cancer Treatment Space Benzinga +9.89%
May-22-17 04:23PM  Why Puma Biotechnology, Applied Optoelectronics, and Ferroglobe Jumped Today Motley Fool +39.15%
04:09PM  Puma Biotech Surges To 6-Month High On Likely Cancer Drug Approval Investor's Business Daily
02:14PM  Puma Biotech Shares Are Roaring On An FDA Review. Here's What Could Still Go Wrong Forbes
01:05PM  Why Puma Biotechnology Inc Jumped Higher Today Motley Fool
11:17AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Puma Biotechnology, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 7, 2017 - PBYI Accesswire
10:41AM  Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote TheStreet.com
10:08AM  Puma Biotechnology Announces Posting of FDA Oncologic Drugs Advisory Committee Briefing Documents for Neratinib Meeting Business Wire
09:00AM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline PBYI GlobeNewswire
08:32AM  Are Options Traders Betting on a Big Move in Puma (PBYI) Stock? Zacks
May-19-17 04:36PM  Harwood Feffer LLP Announces Investigation of Puma Biotechnology, Inc. PR Newswire
May-18-17 07:49PM  PUMA BIOTECHNOLOGY LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Puma Biotechnology, Inc. To Contact The Firm PR Newswire +6.21%
12:01PM  PBYI INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Puma Biotechnology, Inc. and a Lead Plaintiff Deadline of July 7, 2017 Accesswire
08:00AM  Today's Research Reports on Biotech Stocks to Watch: Pulmatrix and Puma Biotechnology Accesswire
May-17-17 05:06PM  Puma Biotechnology Announces Publication of Neratinib Abstract for the 2017 ASCO Annual Meeting Business Wire +13.46%
04:37PM  Puma Leaps On Report Its Breast Cancer Drug Could Rival Roche Investor's Business Daily
10:10AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Puma Biotechnology, Inc. (PBYI) and Lead Plaintiff Deadline: July 7, 2017 GlobeNewswire
09:48AM  Reasons to Add Puma Biotechnology (PBYI) to Portfolio Now Zacks
May-16-17 08:57AM  INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Puma Biotechnology, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 7, 2017 - PBYI Accesswire
May-15-17 02:34PM  Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Puma Biotechnology, Inc. GlobeNewswire
02:18PM  The Klein Law Firm Announces a Class Action Filed on Behalf of Puma Biotechnology, Inc. Shareholders and a Lead Plaintiff Deadline of July 7, 2017 (PBYI) GlobeNewswire
May-12-17 06:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI PR Newswire
08:45AM  PBYI SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Puma Biotechnology, Inc. and a Lead Plaintiff Deadline of July 7, 2017 GlobeNewswire
May-11-17 01:53PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Puma Biotechnology, Inc. (PBYI) and Lead Plaintiff Deadline: July 7, 2017 PR Newswire
11:32AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Puma Biotechnology, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 7, 2017 PBYI GlobeNewswire
08:44AM  Puma (PBYI) Q1 Loss Narrows, Focus Remains on Neratinib Zacks
May-10-17 08:30PM  SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Puma Biotechnology, Inc. (Nasdaq: PBYI) To Contact Brower Piven Before The Lead Plaintiff Deadline GlobeNewswire
07:36PM  Robbins Arroyo LLP: Puma Biotechnology, Inc. (PBYI) Misled Shareholders According to a Recently Filed Class Action Business Wire
05:54PM  Puma Biotech reports 1Q loss Associated Press
04:20PM  Puma Biotechnology Reports First Quarter 2017 Financial Results Business Wire
May-09-17 04:20PM  Puma Biotechnology to Present at Bank of America Merrill Lynch 2017 Health Care Conference Business Wire
May-08-17 11:23PM  PUMA BIOTECHNOLOGY LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Puma Biotechnology, Inc. To Contact The Firm Business Wire -5.54%
04:05PM  PUMA BIOTECHNOLOGY INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Puma Biotechnology, Inc. To Contact The Firm Business Wire
03:16PM  Pomerantz Law Firm Announces the Filing of a Class Action against Puma Biotechnology, Inc. and Certain Officers PBYI GlobeNewswire
May-05-17 05:00PM  Why Puma Biotechnology, Trex, and National CineMedia Slumped Today Motley Fool -16.01%
01:10PM  Why Puma Biotechnology Shares Are Crashing 18.2% Today Motley Fool
12:19PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Puma Biotechnology, Inc. (PBYI) PR Newswire
12:08PM  PUMA BIOTECHNOLOGY INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Puma Biotechnology, Inc. To Contact The Firm PR Newswire
10:19AM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Puma Biotechnology, Inc. - PBYI PR Newswire
06:53AM  A Top Puma Bio Exec Resigns Ahead of FDA Panel, Analysts Defend With Conflicting Stories TheStreet.com
May-03-17 10:44AM  Puma Biotechnology (PBYI) Q1 Earnings: Stock to Disappoint? Zacks -5.00%
Apr-18-17 01:31PM  Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug TheStreet.com -6.94%
Apr-17-17 08:03AM  Puma Biotechnology Announces FDA Advisory Committee to Review Neratinib for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer Business Wire +11.08%
Apr-04-17 01:05PM  Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of PB272 in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2017 AACR Annual Meeting Business Wire
01:05PM  Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of PB272 in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2017 AACR Annual Meeting
Apr-02-17 03:03PM  Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2017 AACR Annual Meeting Business Wire
11:03AM  Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Cancer at the 2017 AACR Annual Meeting Business Wire
10:30AM  Puma Biotechnology Launches Expanded Access Program for PB272 (Neratinib) for U.S. Patients with HER2-Positive Breast Cancer or HER2-Mutated Cancers Business Wire
Mar-24-17 05:00PM  PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and
Mar-20-17 01:00PM  Finding Bullish and Bearish Market Reversals TheStreet.com
01:00PM  Finding Bullish and Bearish Market Reversals
Mar-09-17 07:00AM  7 Stocks Trending Up With Monster Volume TheStreet.com
07:00AM  7 Stocks Trending Up With Monster Volume
Mar-08-17 04:26PM  Puma Leads Massive Biotech Surge As Esperion Hits 15-Month High Investor's Business Daily +13.20%
04:26PM  Puma Leads Massive Biotech Surge As Esperion Hits 15-Month High
Mar-07-17 01:04PM  PUMA BIOTECHNOLOGY, INC. Financials +5.79%
Mar-02-17 05:31PM  Kroger, Shake Shack and Puma dip; Monster Beverage gains Associated Press -13.80%
05:31PM  Kroger, Shake Shack and Puma dip; Monster Beverage gains
04:53PM  Puma (PBYI) Q4 Loss Wider than Expected, Neratinib in Focus Zacks
04:53PM  Puma (PBYI) Q4 Loss Wider than Expected, Neratinib in Focus
04:43PM  Why Puma Biotechnology Inc. Got Hammered Today at Motley Fool
04:20PM  Puma Biotechnology to Present at Cowens Health Care Conference Business Wire
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care. Its drug candidates include PB272 (neratinib (oral)) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 (neratinib (intravenous)). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ADAGE CAPITAL PARTNERS GP, L.L10% OwnerJun 12Sale79.3188,9447,053,8703,696,580Jun 12 06:45 PM
ADAGE CAPITAL PARTNERS GP, L.L10% OwnerJun 09Sale80.7758,3164,710,4303,785,524Jun 12 06:45 PM
ADAGE CAPITAL PARTNERS GP, L.L10% OwnerJun 08Sale80.95100,0008,094,6103,843,840Jun 12 06:45 PM
ADAGE CAPITAL PARTNERS GP, L.L10% OwnerJun 05Sale91.29307,12828,037,0323,943,840Jun 05 05:58 PM
ADAGE CAPITAL PARTNERS GP, L.L10% OwnerJun 02Sale83.0630,4752,531,2874,250,968Jun 05 05:58 PM
ADAGE CAPITAL PARTNERS GP, L.L10% OwnerJun 01Sale82.45169,52513,976,6574,281,443Jun 05 05:58 PM
ADAGE CAPITAL PARTNERS GP, L.L10% OwnerMay 26Sale77.07300,00023,121,2634,450,968May 26 04:40 PM
ADAGE CAPITAL PARTNERS GP, L.L10% OwnerMay 25Sale77.87400,00031,146,5604,750,968May 26 04:40 PM
ADAGE CAPITAL PARTNERS GP, L.L10% OwnerMay 24Sale72.57535,70038,876,4455,150,968May 26 04:40 PM
CHARNAS ROBERTFeb 01Sale31.833,00895,75526,453Feb 02 05:43 PM
Lo StevenChief Commercial OfficerJan 20Sale33.242,29076,10829,210Jan 24 05:56 PM
EYLER CHARLES RSEE REMARKSJan 20Sale33.2482027,2539,680Jan 24 05:53 PM
CHARNAS ROBERTJan 20Sale33.242,29376,20829,407Jan 24 05:52 PM
BRYCE RICHARD PAULSR VP, CLINICAL RESEARCH & DEVJan 20Sale33.242,29376,20829,237Jan 24 05:51 PM
AUERBACH ALAN HPRESIDENT AND CEOJan 20Sale33.2410,202339,0644,179,798Jan 24 05:49 PM